Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Anthracycline-Induced Cardiotoxicity in Breast Cancer
NCT06491680Phase 4Recruiting
- Sponsor
- Helwan University
- Start
- Sep 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in anthracycline-induced cardiotoxicity, sponsored by Helwan University. Started Sep 2024; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
anthracycline-induced cardiotoxicity
Beyond the preview
Go deeper on NCT06491680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06491680.